课题基金 / 基金详情

Safety and efficacy of perinatal gene therapy for Neuronopathic Gaucher disease

Safety and efficacy of perinatal gene therapy for Neuronopathic Gaucher disease
神经病性戈谢病围产期基因治疗的安全性和有效性
批准号:
G1000709/1
负责人:
Simon Waddington
金额:
$62.4万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2010
资助国家:
英国
项目状态:
已结题
起止时间:
2010 至 --

项目摘要

项目成果

Simon Waddington的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Gaucher disease is a genetic disease which, in its severe form, results in serious brain damage infant death before two years of age. The disease is incurable with currently-available drugs since they can?t enter the nerves in the brain. Gene therapy has already been used to cure several genetic diseases and, very recently, it has become possible to deliver genes to the brain. Based on this recent finding, we are trying to cure a mouse model of the human brain disease using gene therapy. We will be injecting the gene into bloodstream of fetal and neonatal mice to see if this prevents the onset of brain disease. If this works it may provide a pathway towards treating human beings; at the very least we will learn more about why the disease damages the brain in infants.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gene therapy for Childhood Parkinsonism: Dopamine transporter deficiency syndrome
  • 批准号:
    MR/R015325/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $63.1万
  • 财政年份:
    2018
  • 负责人:
    Simon Waddington
  • 依托单位:
MICA: Development of gene therapy for the incurable inherited childhood epilepsy, Dravet Syndrome
  • 批准号:
    MR/P026494/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $65.55万
  • 财政年份:
    2017
  • 负责人:
    Simon Waddington
  • 依托单位:
Evaluating the impact of coagulation factors on gene delivery using pseudotyped adenoviruses: receptor usage bioavailability and immunogenicity
  • 批准号:
    BB/E021301/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $36.72万
  • 财政年份:
    2007
  • 负责人:
    Simon Waddington
  • 依托单位:
国内基金
海外基金
噬菌体靶向肠道粪肠球菌提高帕金森病左旋多巴疗效的机制研究
  • 批准号:
    82371251
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    肖勤
  • 依托单位:
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
  • 批准号:
    82370885
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    姚晨
  • 依托单位:
HER2特异性双抗原表位识别诊疗一体化探针研制与临床前诊疗效能研究
  • 批准号:
    82372014
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    魏伟军
  • 依托单位: